By the numbers
0.0M
Medical communitymembers
0K
Curated contentpieces
0M+
Monthlypageviews
By the numbers
0.0M
Medical communitymembers
0K
Curated contentpieces
0M+
Monthlypageviews
TribeMD
Eventos
Notícias em alta
CardiologyMay 11, 2026
4 min read
HF 2026: Back to the Future? DECISION Reignites the Debate on Digoxin in Modern Heart Failure
The four foundational pillars in the treatment of heart failure with reduced ejection fraction (HFrEF) currently represent the standard of modern therapy and include:ACE inhibitors/ARBs or ARNIs + beta-blockers + mineralocorticoid receptor antagonists (MRAs) + SGLT2 inhibitors.Despite the remarkable advances achieved with this quadruple therapy approach, many patients remain symptomatic and continue to experience worsening heart failure episodes and recurrent hospital
OncologyMay 11, 2026
5 min read
Daraxonrasib and Pancreatic Cancer: A New Signal Against a Historically Difficult Target
Pancreatic ductal adenocarcinoma remains one of the most challenging malignancies in oncology. Many patients are diagnosed at an advanced stage, and therapeutic options following progression on chemotherapy still offer limited benefit. In this context, any strategy capable of targeting a central biological driver of the disease deserves careful attention.
CardiologyMay 7, 2026
3 min read
TRIDENT Trial: Low-Dose Polypill Strategy Reduces Stroke Recurrence After Intracerebral Hemorrhage
Intracerebral hemorrhage (ICH) remains one of the most devastating forms of stroke, associated with high morbidity, mortality, and a substantial risk of recurrence. To date, strict blood pressure control remains the only strategy consistently proven to be effective for secondary prevention in this setting. Within this context, the TRIDENT trial emerges as a landmark study by investigating an innovative approach based on a fixed-dose combination of three low-dose antihypertensive agents in a s
CardiologyMay 7, 2026
4 min read
Postoperative Atrial Fibrillation: A Transient Arrhythmia or a Marker of Atrial Vulnerability?
Intracerebral hemorrhage (ICH) remains one of the most devastating forms of stroke, associated with high morbidity, mortality, and a substantial risk of recurrence. To date, strict blood pressure control remains the only strategy consistently proven to be effective for secondary prevention in this setting. Within this context, the TRIDENT trial emerges as a landmark study by investigating an innovative approach based on a fixed-dose combination of three low-dose antihypertensive agents in a s